Risk score based on ten lncRNA-mRNA expression predicts the survival of stage II-III colorectal carcinoma

• Published in: PloS one Vol. 12; no. 8; p. e0182908
• Main Authors: Diao, Ruigang, Mu, Xiaodong, Wang, Tingting, Li, Shuqing
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 10.08.2017; Public Library of Science (PLoS)
• Subjects: Adult; Age Factors; Aged; Aged, 80 and over; Biology; Biology and life sciences; Breast cancer; Cell adhesion; Cell adhesion & migration; Chemotherapy; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - genetics; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Consumer credit; Datasets; DNA microarrays; Female; Gene expression; Gene set enrichment analysis; Genomes; Humans; Male; Mathematical models; Medical prognosis; Medical research; Medicine and Health Sciences; Messenger RNA; Metastasis; Middle Aged; Neoplasm Staging; Pathology; Patient outcomes; Patients; Performance evaluation; Prognosis; Quality; Regression analysis; Risk; Risk Assessment; Risk factors; Risk groups; RNA, Long Noncoding; Sex Factors; Survival; Survival Rate
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0182908

The prognosis of colorectal carcinoma (CRC) is unstable in the stage II-III patients. Patients with early stage II CRC have a relative poor prognosis while other stage III CRC patients have a better prognosis. In our work, by utilizing the expression of lncRNAs and mRNAs measured by microarray (GSE39582), we constructed a risk score staging system with Cox multivariate regression model to predict the outcome of grade II-III CRC patients. Ten genes including two lncRNAs and eight mRNAs were used to estimate the survival of stage II-III CRC patients. The patients with high risk scores have poorer survival rate those with low risk scores, significantly. These results were further validated in another three independent datasets (GSE37892, GSE33113, and GSE17536). The relationship between clinical information and were evaluated, and the risk score is independent from the other clinical information and performs better in evaluating the survival of stage II-III CRC patients. Moreover, the correlation between chemotherapy was also evaluated, and we found that both patients with or without chemotherapy have a poor survival in high risk group. Gene Set Enrichment Analysis were used to find the difference between high-risk and low-risk groups, and pathways including cell adhesion and focal adhesion were significantly enriched, suggesting that the risk score reflects the status of cell-cell physical interaction. In summary, we constructed a risk staging model for grade II-III CRC, which is independent from and performs better than clinical information.